In Vitro Activity of Tedizolid Against Gram-Positive Bacteria in Patients With Skin and Skin Structure Infections and Hospital-Acquired Pneumonia: A Korean Multicenter Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We compared the activities of tedizolid to those of linezolid and other commonly used antimicrobial agents against gram-positive cocci recovered from patients with skin and skin structure infections (SSSIs) and hospital-acquired pneumonia (HAP) in Korean hospitals. Gram-positive isolates were collected from 356 patients with SSSIs and 144 patients with HAP at eight hospitals in Korea from 2011 to 2014. SSSIs included impetigo, cellulitis, erysipelas, furuncles, abscesses, and infected burns. Antimicrobial susceptibility was tested by using the CLSI agar dilution method. All of the gram-positive isolates were inhibited by ≤1 μg/mL tedizolid. The minimum inhibitory concentration [MIC]90 of tedizolid was 0.5 μg/mL for methicillin-resistant Staphylococcus aureus, which was 4-fold lower than that of linezolid. Tedizolid may become a useful option for the treatment of SSSIs and HAP caused by gram-positive bacteria.
Abstract
We compared the activities of tedizolid to those of linezolid and other commonly used antimicrobial agents against gram-positive cocci recovered from patients with skin and skin structure infections (SSSIs) and hospital-acquired pneumonia (HAP) in Korean hospitals. Gram-positive isolates were collected from 356 patients with SSSIs and 144 patients with HAP at eight hospitals in Korea from 2011 to 2014. SSSIs included impetigo, cellulitis, erysipelas, furuncles, abscesses, and infected burns. Antimicrobial susceptibility was tested by using the CLSI agar dilution method. All of the gram-positive isolates were inhibited by ≤1 μg/mL tedizolid. The minimum inhibitory concentration [MIC]90 of tedizolid was 0.5 μg/mL for methicillin-resistant Staphylococcus aureus, which was 4-fold lower than that of linezolid. Tedizolid may become a useful option for the treatment of SSSIs and HAP caused by gram-positive bacteria.
참고문헌 (15)
- Rajan S, "Skin and soft-tissue infections: classifying and treating a spectrum", Cleve Clin J Med, 79, pp.57~66 (2012)
- Rubinstein E, "Pneumonia caused by methicillin-resistant Staphylococcus aureus", Clin Infect Dis, 46(S5), pp.S378~385 (2008)
- Mendes RE, "Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States", Antimicrob Agents Chemother, 58, pp.1243~1247 (2014)
- Gu B, "The emerging problem of linezolid-resistant Staphylococcus", J Antimicrob Chemother, 68, pp.4~11 (2013)
- Moravvej Z, "Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains", Int J Antimicrob Agents, 42, pp.370~371 (2013)
- Rodríguez-Avial I, "In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci", J Antimicrob Chemother, 67, pp.167~169 (2012)
- Shaw KJ, "In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains", Antimicrob Agents Chemother, 52, pp.4442~4447 (2008)
- Moellering RC Jr., "Tedizolid: a novel oxazolidinone for Gram-positive infections", Clin Infect Dis, 58(S1), pp.S1~3 (2014)
- Kisgen JJ, "Tedizolid: a new oxazolidinone antimicrobial", Am J Health Syst Pharm, 71, pp.621~633 (2014)
- Yum JH, "Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea", Antimicrob Agents Chemother, 54, pp.5381~5386 (2010)
- US Food and Drug Administration, "Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment", US Food and Drug Administration, ~ (2010)
- Goldstein EJ, "Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin", Clin Infect Dis, 53, pp.1074~1080 (2011)
- Brook I, "Antianaerobic antimicrobials: spectrum and susceptibility testing", Clin Microbiol Rev, 26, pp.526~546 (2013)
- "Sivextro (tedizolid) Prescribing information" (2014), Cubist Pharmaceuticals
- Thomson KS, "Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins", Antimicrob Agents Chemother, 57, pp.2892~2895 (2013)